Back to News
Market Impact: 0.3
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
Source: GlobeNewswire
Healthcare & BiotechCorporate Guidance & Outlook
The PREDICT-1 registrational trial of licaminlimab, a genotype-based precision-medicine approach for TNFR1-mediated dry eye disease, remains on track for a topline readout around year-end. The headline provides a development timeline but no trial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Levi Strauss hikes profit guidance after tariff refunds, but its sales outlook is less optimistic
- Streamex CIO Mitchell Williams sells $35,239 in company stock
- Another Micron triple? Where we agree with this wildly bullish call and where we don't
- Levi Strauss lifts annual profit outlook on tariff refunds, holiday demand
- Profound Medical stock surges 20% on raised Q3 revenue outlook
- Marvell just gave a bullish outlook. It led TD Cowen to upgrade the stock